Fig. 6: PFS according FLC status at the end of induction chemotherapy, day + 100 post-ASCT and 6 months post maintenance randomisation. | Blood Cancer Journal

Fig. 6: PFS according FLC status at the end of induction chemotherapy, day + 100 post-ASCT and 6 months post maintenance randomisation.

From: Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry

Fig. 6: PFS according FLC status at the end of induction chemotherapy, day + 100 post-ASCT and 6 months post maintenance randomisation.

A–C Show the PFS for IFE-negative patients with a normal versus abnormal serum FLC ratio at the end of induction chemotherapy, day+100 post-ASCT and six months post maintenance randomisation. D–F show the PFS for IFE negative with patients with a normal FLC ratio (classified as a normal serum FLC ratio or an abnormal serum FLC ratio due to suppression of the uninvolved FLC) versus an abnormal FLC ratio at the end of induction chemotherapy, day+100 post-ASCT and six months post maintenance randomisation. G–I show the PFS for IFE-negative patients according to FLC-MS status at the end of induction chemotherapy, day+100 post-ASCT and six months postmaintenance randomisation.

Back to article page